Nanfang Hospital, Southern Medical University: Carcinoma trials
The registry lists 20 Carcinoma studies with Nanfang Hospital, Southern Medical University as lead sponsor. 11 are open to participants now and 0 have results posted.
Phase 2 11Phase 3 2No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular CarcinomaRecruitingNCT06864221
- A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06843889Phase 2
- Correlation Study of Lipid Metabolites as Markers of Hepatocellular CarcinomaRecruitingNCT06623474
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 2
- Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell CarcinomaRecruitingNCT06142318Phase 2
- Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal CarcinomaNot yet recruitingNCT05996484Phase 2
- Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT05773079Phase 2
- Pembrolizumab Plus Radiotherapy for Advanced Renal CancerRecruitingNCT05567588Phase 2
- Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
- Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT04221516Phase 2
- Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaRecruitingNCT03919552Phase 3
- Prognostic Value of Tumor Deposits for Patients With Papillary Thyroid CarcinomaCompletedNCT06051838
- Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell CarcinomaStatus unknownNCT05578170
- Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
- Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253Status unknownNCT04848311Not applicable
- Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）Status unknownNCT04806243Phase 2
- Observational Study on Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT04021056
- Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular CarcinomaStatus unknownNCT03285867
- IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal CarcinomaStatus unknownNCT03068936Phase 3